Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma

Journal of Nuclear Medicine

Volumn 50, Issue 12, 2009, Pages 1962-1968

  Ullrich, Roland T ^a,b   Kracht, Lutz ^a   Brunn, Anna ^b   Herholz, Karl ^c   Frommolt, Peter ^b   Miletic, Hrvoje ^d,e   Deckert, Martina ^b   Heiss, Wolf Dieter ^a   Jacobs, Andreas H ^a,b,f,g  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f KLINIKUM FULDA   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

11C MET; Angiogenesis; Gliomas; Malignant progression; PET

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ECAT EXACT; GADOLINIUM PENTETATE MEGLUMINE; IOPAMIDOL; METHIONINE C 11; MOLECULAR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; METHIONINE; METHIONINE METHYL ESTER;

ADULT; ANGIOGENESIS; ARTICLE; ASTROCYTOMA; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE SEVERITY; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; NEUROSURGERY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BIOPSY; ADOLESCENT; CHILD; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADOLESCENT; ADULT; BIOLOGICAL TRANSPORT; CHILD; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 73349114302     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.065904     Document Type: Article

References (31)

1. Statistical Report: Primary Brain Tumors in the United States, 1997-2001. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2004.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
3. Tsuyuguchi N, Takami T, Sunada I, et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery: in malignant glioma. Ann Nucl Med. 2004;18: 291-296.
4. Jacobs AH, Kracht LW, Gossmann A, et al. Imaging in neurooncology. NeuroRx. 2005;2:333-347.
5. Jacobs AH, Li H, Winkeler A, et al. PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging. 2003;30:1051-1065.
6. Thiel A, Pietrzyk U, Sturm V, Herholz K, Hovels M, Schroder R. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report. Neurosurgery. 2000;46:232-234.
7. 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39-51.
8. Miyagawa T, Oku T, Uehara H, et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab. 1998;18:500-509.
9. 11C]-l- methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30:868-873.
10. 11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10:7163-7170.
11. 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev. 1999;22:210-214.
12. 11C]L-methionine uptake in gliomas. Neurosurgery. 1989;25:720-728.
13. Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology. 1993;186:45-53.
14. 11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. Am J Neuroradiol. 2006;27:1432-1437.
15. Wienhard K, Eriksson L, Grootoonk S, Casey M, Pietrzyk U, Heiss WD. Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr. 1992;16:804-813.
16. Wienhard K, Dahlbom M, Eriksson L, et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr. 1994;18:110-118.
17. 11C-labelled radiopharmaceuticals: imipramine, chlorpromazine, nicotine and methionine. Int J Appl Radiat Isot. 1979;30:393-399.
18. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322.
19. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res. 1997;3:523-530.
20. McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J. Treatment and survival of low-grade astrocytoma in adults: 1977-1988. Neurosurgery. 1992;31:636-642.
21. Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene. 2004;23:4624-4635.
22. Kim BW, Choi M, Kim YS, et al. Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin. Cell Signal. 2008;20:714-725.
23. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254-266.
24. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res. 2002;62:6764-6769.
25. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353: 2012-2024.
26. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25:5220-5227.
27. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64:6892-6899.
28. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005;437:497-504.
29. Rosenstein JM, Mani N, Silverman WF, Krum JM. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci USA. 1998;95:7086-7091.
30. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445.
31. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947-949.